无限的可乐
Lv53
840 积分
2023-07-18 加入
-
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials
1天前
已完结
-
Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials
10天前
已完结
-
嗜酸性粒细胞性食管炎的诊断及治疗
10天前
已完结
-
慢性鼻窦炎伴鼻息肉的生物靶向治疗
10天前
已完结
-
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
14天前
已完结
-
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
14天前
已完结
-
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
14天前
已完结
-
中国带状疱疹诊疗专家共识(2022版)
14天前
已完结
-
小分子药物开发中的药物代谢及代谢产物安全性评价
15天前
已关闭
-
Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: Results from two phase 3 studies
16天前
已完结